Diana Isaacs, PharmD: An Overview of Insulin Affordability in 2020

Video

A look at the state of insulin affordability in 2020 and how the ongoing pandemic has impacted the situation.

The affordability of insulin is a constant topic of discussion for diabetics and their care providers. While the cost of medication was already an issue for many diabetic patients, it has been further compounded by the ongoing coronavirus disease 2019 (COVID-19) pandemic.

In the following interview, Diana Isaacs, PharmD, a clinical pharmacist and diabetes care and education specialist at the Cleveland Clinic, discusses the affordability of insulin and how the ability of patients to afford their medications has been impacted by the pandemic. A leader in her field, Isaacs offers perspective on topics from how to approach these delicate conversations with patients to the best resources for patients who may be struggling to afford their insulin.

Related Videos
Vlado Perkovic, MBBS, PhD | Credit: George Institute of Global Health
Should We Reclassify Diabetes Subtypes?
What Should the American Academy of Physician Associates Focus on in 2025?
GLP-1 Agonist Safety Risks and Obesity Stigma with Kevin Peterson, MD, MPH
Video 8 - "Pathophysiology of Hypercortisolism"
Video 7 - "Evolving Perception of Autonomous Adrenal Hypercortisolism "
A panel of 5 experts on Cushing's syndrome
A panel of 5 experts on Cushing's syndrome
Roger S. McIntyre, MD: GLP-1 Agonists for Psychiatry?
Daniel Gaudet, MD, PhD | Credit: American College of Cardiology
© 2024 MJH Life Sciences

All rights reserved.